Lonza plans to create new jobs at Stücki Park
Swiss Prime Site is about to create additional office and laboratory space for 1,700 new jobs at Stücki Park in Basel. The chemical specialists Lonza will rent space to hire an additional 250 specialists from 2020.
Stücki Park (img: Florian Lotter)
Stücki Park is being expanded further. Swiss Prime Site has announced in a press release that 190 million Swiss francs will be invested in expanding the existing laboratory and office space. This will see the rental area more than doubled by 33,000 square meters to a total of 60,000 square meters by 2023, thereby creating space for 1,700 new jobs at the site in north Basel.
The chemical specialists Lonza, already an established presence at Stücki Park as anchor tenants, will rent new buildings across a surface area of 8,000 square meters. From the third quarter of 2020, around 250 new specialists will work in the new buildings, “thus further enhancing Basel as a major economic area”, as Prof. Dr. Hanns-Christian Mahler, Head of Lonza Drug Product Services, commented in the press release. “As we continue to grow in Drug Product Services, the new buildings at Stücki Park are ideal for us”, he concluded.
Peter Lehmann, CEO Swiss Prime Site Immobilien, was delighted about Lonza’s expansion, commenting in the press release: “The complete rental of the existing long building and a substantial part of the new building represents a significant milestone for the site, which this project will make considerably more attractive”.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More